Home > Cytrx Salary

Cytrx Salary

  • 20
  • 53
  • 50
Cytrx average salary is $62,544, median salary is $57,138 with a salary range from $55,494 to $75,000.
Cytrx salaries are collected from government agencies and companies. Each salary is associated with a real job position. Cytrx salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
55,494
Average
62,544
Median
57,138
High
75,000
Total 3 Cytrx Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Clinical Operations Scientist 75,000-75,000 Fair Lawn, NJ, 07410 2016 Cytrx Clinical Operations Scientist Salaries (1)
Cytrx Fair Lawn, NJ Salaries
Pharma-chemical Marketing Assistant Manager 55,494-55,494 Fair Lawn, NJ, 07410 2013 Cytrx Pharma-chemical Marketing Assistant Manager Salaries (1)
Cytrx Fair Lawn, NJ Salaries
Accountant 57,138-57,138 Fair Lawn, NJ, 07410 2012 Cytrx Accountant Salaries (1)
Cytrx Fair Lawn, NJ Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Cytrx salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Cytrx Jobs
See more Cytrx Jobs»
Search All Jobs

JobsOpenHiring – Find open jobs faster
Cytrx... Information
  • CytRx Corporation
  • Industry: BioTech/Drugs
  • City: Los Angeles, CA
  • CytRx Corporation is a biopharmaceutical company engaged in the development and commercialization of large market opportunity products in a variety of therapeutic categories. The company recently has formed a broad- based strategic alliance with the University of Massachusetts Medical School to develop novel compounds for obesity, diabetes and oncology based on a promising new technology known as RNA interference (RNAi). CytRx is seeking strategic partners to complete the development of FLOCOR, a product for the treatment of sickle cell disease and which may have applications in cancer and disorders such as stroke and heart attack. The company has licensed its